Minerva NeurosciencesNERV -0.23%32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates NERV with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Minerva Neurosciences ranks worse than 105820% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Minerva Neurosciences EBITDA Margin % Related Terms
Minerva Neurosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Minerva Neurosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NERV vs YDES, CAMP, IKT: EBITDA Margin % Comparison
For the Biotechnology subindustry, Minerva Neurosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minerva Neurosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Minerva Neurosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minerva Neurosciences (NERV) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Minerva Neurosciences and its competitors. Over the past decade, Minerva Neurosciences' EBITDA Margin % has ranged from 5.14 to 5.14. According to the industry distribution chart, Minerva Neurosciences ranks #999999 out of 945 companies in the Biotechnology industry.
Is Minerva Neurosciences' EBITDA Margin % too high?
Minerva Neurosciences' current EBITDA Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 5.14 to a high of 5.14. Based on the distribution chart, Minerva Neurosciences ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Minerva Neurosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Minerva Neurosciences' EBITDA Margin % compare to YDES and CAMP?
According to the Biotechnology industry distribution chart, Minerva Neurosciences ranks #999999 out of 945 companies for EBITDA Margin %. This places Minerva Neurosciences in the lower half of its industry. Historically, Minerva Neurosciences' own EBITDA Margin % has ranged from 5.14 to 5.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Minerva Neurosciences and its competitors. Minerva Neurosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Neurosciences stock overvalued right now?
Minerva Neurosciences (NERV) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Minerva Neurosciences' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Minerva Neurosciences (NERV), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
32GF Score
Get the complete analysis for NERV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NERV has been successfully added to your 
